Vardigan J - Search Results

1

Translational Pharmacokinetic-Pharmacodynamic Modeling of NaV1.7 Inhibitor MK-2075 to Inform Human Efficacious Dose.

Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, Jochnowitz N, Kraus RL, Klein RM, Henze DA, Houghton AK, Burgey CS, Gibson C, Struyk A. Ballard JE, et al. Among authors: vardigan j. Front Pharmacol. 2021 Dec 24;12:786078. doi: 10.3389/fphar.2021.786078. eCollection 2021. Front Pharmacol. 2021. PMID: 35002718 Free PMC article.

2

Pharmacological validation of a novel nonhuman primate measure of thermal responsivity with utility for predicting analgesic effects.

Vardigan JD, Houghton AK, Lange HS, Adarayan ED, Pall PS, Ballard JE, Henze DA, Uslaner JM. Vardigan JD, et al. J Pain Res. 2018 Apr 11;11:735-741. doi: 10.2147/JPR.S152879. eCollection 2018. J Pain Res. 2018. PMID: 29692626 Free PMC article.

3

Pharmacological Characterization of the Novel and Selective α7 Nicotinic Acetylcholine Receptor-Positive Allosteric Modulator BNC375.

Wang X, Daley C, Gakhar V, Lange HS, Vardigan JD, Pearson M, Zhou X, Warren L, Miller CO, Belden M, Harvey AJ, Grishin AA, Coles CJ, O'Connor SM, Thomson F, Duffy JL, Bell IM, Uslaner JM. Wang X, et al. Among authors: vardigan jd. J Pharmacol Exp Ther. 2020 May;373(2):311-324. doi: 10.1124/jpet.119.263483. Epub 2020 Feb 24. J Pharmacol Exp Ther. 2020. PMID: 32094294

4

Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate.

Ballard JE, Pall P, Vardigan J, Zhao F, Holahan MA, Kraus R, Li Y, Henze D, Houghton A, Burgey CS, Gibson C. Ballard JE, et al. Among authors: vardigan j. Pharm Res. 2020 Sep 4;37(10):181. doi: 10.1007/s11095-020-02914-9. Pharm Res. 2020. PMID: 32888082 Free PMC article.

5

Na_v1.7 target modulation and efficacy can be measured in nonhuman primate assays.

Kraus RL, Zhao F, Pall PS, Zhou D, Vardigan JD, Danziger A, Li Y, Daley C, Ballard JE, Clements MK, Klein RM, Holahan MA, Greshock TJ, Kim RM, Layton ME, Burgey CS, Serra J, Henze DA, Houghton AK. Kraus RL, et al. Among authors: vardigan jd. Sci Transl Med. 2021 May 19;13(594):eaay1050. doi: 10.1126/scitranslmed.aay1050. Sci Transl Med. 2021. PMID: 34011626

6

Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.

Lange HS, Vardigan JD, Cannon CE, Puri V, Henze DA, Uslaner JM. Lange HS, et al. Among authors: vardigan jd. Neuropharmacology. 2021 Oct 1;197:108754. doi: 10.1016/j.neuropharm.2021.108754. Epub 2021 Aug 11. Neuropharmacology. 2021. PMID: 34389398

7

MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?

Vardigan JD, Huszar SL, McNaughton CH, Hutson PH, Uslaner JM. Vardigan JD, et al. Pharmacol Biochem Behav. 2010 Apr;95(2):223-9. doi: 10.1016/j.pbb.2010.01.010. Epub 2010 Feb 1. Pharmacol Biochem Behav. 2010. PMID: 20122952

8

Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease.

Cramer PE, Gentzel RC, Tanis KQ, Vardigan J, Wang Y, Connolly B, Manfre P, Lodge K, Renger JJ, Zerbinatti C, Uslaner JM. Cramer PE, et al. Among authors: vardigan j. Neurobiol Aging. 2018 Apr;64:92-106. doi: 10.1016/j.neurobiolaging.2017.12.011. Epub 2017 Dec 20. Neurobiol Aging. 2018. PMID: 29353102

9

Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.

Rudd MT, Manley PJ, Hanney B, Meng Z, Shu Y, de Leon P, Frie JL, Han Y, Wai JM, Yang ZQ, Perkins JJ, Hurzy DM, Manikowski JJ, Zhu H, Bungard CJ, Converso A, Meissner RS, Cosden ML, Hayashi I, Ma L, O'Brien J, Uebele VN, Schachter JB, Bhandari N, Ward GJ, Fillgrove KL, Lu B, Liang Y, Dubost DC, Puri V, Eddins DM, Vardigan JD, Drolet RE, Kern JT, Uslaner JM. Rudd MT, et al. Among authors: vardigan jd. ACS Med Chem Lett. 2023 Jul 12;14(8):1088-1094. doi: 10.1021/acsmedchemlett.3c00210. eCollection 2023 Aug 10. ACS Med Chem Lett. 2023. PMID: 37583812

10

Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants.

Uslaner JM, Smith SM, Huszar SL, Pachmerhiwala R, Hinchliffe RM, Vardigan JD, Hutson PH. Uslaner JM, et al. Psychopharmacology (Berl). 2009 Nov;206(4):641-51. doi: 10.1007/s00213-009-1644-y. Epub 2009 Aug 26. Psychopharmacology (Berl). 2009. PMID: 19707745

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page